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Abstract 
Background: Targeted genomic editing using the CRISPR/Cas9 methodology has opened exciting new avenues in 
probing gene function in virtually any model system, including cultured mammalian cells. Depending on the desired 
mutation, several experimental options exist in the isolation of clonal lines, such as selection with introduced markers, 
or screening by PCR amplification of genomic DNA. However, streamlined approaches to establishing deletion and 
tagging mutants with minimal genomic perturbation are of interest in applying this methodology.
Results: We developed a procedure for rapid screening of clonal cell lines for the deletion of a protein of inter-
est following CRISPR/Cas9 targeting in the absence of selective pressure based on dot immunoblots. To assess the 
technique, we probed clonal isolates of 293-TREx cells that were targeted with three separate sgRNAs against the 
HuR gene. Validation of knockout candidates by western blot indicated that the normalized protein abundances 
indicated by the dot blot serve as accurate predictors of deletion. In total, 32 independent biallelic deletion lines out 
of 248 screened clones were isolated, and recovery of null mutants ranged from 6 to 36 % for the individual sgRNAs. 
Genomic sequencing verified small deletions at the targeted locus.
Conclusions: Clonal screening for CRISPR/Cas9-mediated editing events using dot immunoblot is a straightforward 
and efficient approach that facilitates rapid generation of genomic mutants to study gene function.
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Background
Manipulating protein levels and activities is a principal 
tool in understanding the functions and the relation-
ships of these molecular components in cells. Transient 
perturbations involve chemical inhibition (and activa-
tion) with small molecules, overexpression from non-
integrating vectors, or knockdown by RNA interference 
[1]. Often more experimentally desirable, stable genetic 
alteration can be achieved by integration of overexpres-
sion and shRNA constructs [2], or by genomic editing 
of the endogenous protein locus with transcription acti-
vator-like effector nucleases (TALENs) [3], zinc-finger 
nucleases [4, 5], and, more recently, by RNA-guided 
nucleases based on the clustered, regularly interspaced 
short palindromic repeats (CRISPR)/Cas9 system [6–11]. 
Combinations of stable integration and modification with 
temporal control include the use of chemically inducible 
systems, such as tetracycline repression/activation [12, 
13], tamoxifen control of Cre-ER recombination [14, 15], 
and more modular control of expression, localization and 
activity by small molecules [16–18].
The CRISPR/Cas module is an endogenous adap-
tive immunity system commonly used by bacteria and 
archaea to counteract phage infection and introduction 
of plasmid DNA [19–22]. Short (20–30  bp) sequence 
tags from the invaders are incorporated as spacers 
between direct repeats of a CRISPR locus. Its transcrip-
tion and processing yields small crRNAs that associate 
with and guide CRISPR-associated (cas) protein(s) to 
complementary DNA targets for endonucleolytic cleav-
age. Due to its particularly simple makeup, the type II 
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CRISPR/Cas system of Streptococcus pyogenes has been 
adapted for genomic editing with great success: a single 
protein, Cas9, is required for crRNA binding and cleav-
age, and the RNA components have been engineered 
into a single guide RNA (sgRNA) [23]. Thus, targeting of 
nearly any genomic sequence is possible with the intro-
duction of an sgRNA and Cas9 into the cells of inter-
est [24, 25]. In its simplest form, creation of a knockout 
line depends on the sgRNA-guided dsDNA cleavage by 
the Cas endonuclease, followed by non-homologous 
end joining (NHEJ) repair of the site by the cell. A small, 
random deletion is often introduced at the repair site. 
Deletions that target the open reading frame and result 
in frame-shifts, particularly early in the mRNA, are very 
likely to yield a non-functional protein sequence and 
to target the mRNA for nonsense-mediated decay due 
to premature stop codons in the new frame (Fig. 1). In 
contrast, small in-frame deletions may not compromise 
the function of the protein. Aside from NHEJ-mediated 
deletions, the Cas cleavage can also stimulate homol-
ogy-driven repair based on a supplied DNA template, 
and allow for larger deletions or insertion of tags and 
markers.
In the targeted modification strategies, the researcher 
has the option to isolate correct clones by introduc-
ing a selectable marker at the genomic locus. While this 
approach is beneficial if the sgRNA has low efficiency, or 
if the mutation confers a strong selective disadvantage to 
the cells, it requires the construction of repair template 
vectors containing the marker and homology arms spe-
cific to the locus [26]. Furthermore, it leaves a signifi-
cantly-sized, transcribed insertion that may affect the 
expression of nearby genes, although it may be excised 
through an additional Cre-mediated step, if surrounded 
by loxP sites [27].
However, the relatively high efficiency of Cas9 target-
ing allows for clonal screening without selection. In a 
common approach, purification of genomic DNA from 
isolated clones permits PCR amplification followed by 
sequencing, deletion analysis or restriction digest [28]. In 
the present study, we describe a simple method for iso-
lation of clonal deletion mutants based on CRISPR/Cas9 
targeting combined with dot immunoblot analysis and 
validated by western blots and DNA sequencing. Screen-
ing directly for protein production ensures proper knock-
out, avoiding signal from in-frame deletions/mutations 
Fig. 1 sgRNA/Cas9-mediated gene knockouts. sgRNA/Cas9 targeting to a gene exon induces a double-stranded DNA break that is repaired by 
non-homologous end joining, often introducing frameshift mutations (depicted in red) that lead to lack of functional protein production and likely 
cause nonsense-mediated decay of the mRNA
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that may not eliminate its function. The approach can 
also be applied to screening for insertions of tags medi-
ated by homologous recombination.
Results and discussion
We wished to apply the CRISPR/Cas system to establish 
stable cell lines completely lacking specific protein func-
tion. As with other genetic mutant approaches, it is ben-
eficial to isolate several independently derived knockout 
clones to control for secondary mutations. In the case of 
CRISPR/Cas, off-target cleavage events at sites of imper-
fect sgRNA complementarity are known to occur [29, 
30], and the use of different sgRNAs can mitigate the 
possibility of spuriously observed phenotypes. We used 
pre-designed human genomic target sites for the S. pyo-
genes Cas9 effector nuclease, picking the reduced set of 
three sites closer to the 5′ end of the gene [31]. The tar-
geted sites were introduced into sgRNA-producing con-
text in a plasmid that also co-expresses the Cas9 protein, 
pSpCas9(BB) [24, 28].
We opted to develop a simple, selection-free strategy 
based on dot blots for the protein of interest to isolate 
the knockout clones (Fig. 2a). First, a bulk population of 
cells is transfected with the sgRNA/Cas9 constructs. To 
ensure a high percentage of expressing cells, the transfec-
tion procedure may be sequentially repeated, and a paral-
lel control transfection with a GFP marker is performed. 
Next, transfected cells are plated at limiting dilution con-
centrations into 96-well plates, and clonal populations are 
established. Setting aside a propagating aliquot for each, 
confluent clones are lysed in the plate with a passive lysis 
buffer. To identify knockout candidates, a small amount 
of lysate (1  µl) is blotted onto two nitrocellulose mem-
branes, to be immunoblotted for the protein of interest, 
and a normalization control. Alternatively, a single mem-
brane may be probed sequentially. Clones that exhibit lit-
tle or no expression of the protein, while demonstrating 
a measurable amount of cell extract in the control blot, 
can be identified visually, or by quantifying the ratio of 
the corresponding dot intensities. In this fashion, screen-
ing directly for protein production ensures a functional 
knockout, as opposed to deletions/mutations that may 
not efficiently disrupt the protein. It should be noted that 
the extent of cross-reactivity of the antibody will affect 
Fig. 2 Identification of knockout lines by protein dot blot. a Schematic of the procedure: after transfection, cells are plated at limiting dilution 
in 96-well plates, and isolated colonies are picked and expanded. Lysates from clonal populations are blotted on a nitrocellulose membrane and 
probed for the protein of interest, along with a parallel control protein blot. b One batch of isolated clones (from a total of two) is shown after dot 
blotting with HuR antibody (left), and separate blotting for a control protein, Pum2 (right). Clones with insufficient control protein signal (<two fold 
of the membrane background), denoted by an x, likely arose due to pipetting or blotting error, and were excluded from further analysis. Circles 
denote clones that validated (green) or did not validate (grey) by subsequent western blot. Clone HuR-5.B5 is designated by a star. Boxes around the 
blots indicate clones isolated from HuR-3, 4, and 5 targeting constructs (from top to bottom respectively)
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the accuracy of the method, since genuine knockout lines 
may still display a significant level of background signal 
from other proteins in the blot.
We applied the above strategy to generate a knockout 
of the HuR (ELAVL1) protein in 293-TREx cells, target-
ing exons 3, 4, and 5 with three distinct sgRNAs. Most 
of the expanded clones exhibited parental growth rates 
and morphology, while several lines grew substantially 
slower and/or with altered cell shape. However, these 
features did not correlate with the absence of HuR (see 
below), likely reflecting spurious mutations acquired due 
to CRISPR/Cas off-targeting or simply during the proce-
dure. Thus, HuR is dispensable to normal growth rates 
under optimal conditions in 293-TREx cells; however, if 
the protein of interest is expected to affect the division 
or morphology of cells, it can form the basis of a pheno-
typic pre-screen during clonal expansion. Mutations that 
are substantially detrimental to growth rates can still be 
recovered, since the clonal isolation begins soon after the 
introduction of the sgRNA/Cas9.
Isolated clones were grown and tested for the pres-
ence of HuR with a dot blot (Fig. 2b, left), yielding several 
candidates with complete or near-complete lack of HuR 
(circled). In addition to visual inspection, HuR expression 
signal on the dot blots was quantified relative to a loading 
control (Fig. 2b, right). After eliminating clones with low 
control expression (less than twofold of the average back-
ground staining of the blot), the ratios displayed a range 
of  >104-fold in normalized HuR expression (Fig.  3a). A 
possible expectation was for the HuR levels to cluster into 
stepwise values representing wild-type, heterozygous, 
and homozygous mutant clones. Instead, the observed 
levels form a fairly smooth gradient, likely due to clonal 
variability in expression, as well as probable compen-
satory mechanisms affecting expression in heterozy-
gotes. Of note, our estimates based on absolute protein 
quantification in the literature [32] indicate that  ~300 
fmol (11  pg) of HuR were blotted, and we expect that 
substantially lower protein amounts should be reliably 
detected, provided suitable antibodies are available.
Forty four of the 248 identified candidates (examples 
shown in Fig.  2b, circles), including some with low but 
visible signal in the dot blot, were further tested for the 
absence of HuR by western blot (example in Fig.  3b). In 
an all-or-none fashion, 32 clones validated as complete 
knockouts, while 12 appeared to be false positives. The 
false positives may have resulted from pipetting error dur-
ing blotting; from stochastically low, but non-zero HuR 
expression in some wild-type clones; and from select-
ing clones with comparatively fewer cells in the lysate 
(observed as low expression both for HuR and the con-
trol). Indeed, the validated KO lines had significantly 
lower normalized HuR signal (this remaining signal likely 
arising from antibody cross-reactivity) relative to the can-
didates that were not confirmed (Fig. 3a). This indicated 
that the HuR/control ratio is an accurate quantitative cri-
terion in separating true knockouts from wild-type clones 
in our broad set of tested candidates, and can serve as a 
reliable selection filter. It should be noted that a modifica-
tion to the procedure that would strip and re-probe the 
same blot for both proteins could eliminate some of the 
signal variability, at the expense of a slightly lengthier pro-
tocol. Finally, we verified the deletions in clone HuR-5.B5 
by amplifying, cloning and sequencing the corresponding 
genomic region (Fig. 4). Four sequenced clones revealed 
two different short deletions, consistent with independ-
ent NHEJ events at two chromosomal locations. In both 
cases, the deletions occurred near the Cas9 cleavage site 
three nucleotides upstream of the protospacer-adjacent 
motif (NGG) [23, 33], as observed previously [24].
The effectiveness of generating homozygous knock-
outs varied substantially with the sgRNA used (Table 1), 
Fig. 3 Quantification and validation of KO candidates. a Ratios of HuR to control protein signal in the dot blot shown in Fig. 2b, in increasing order. 
Clones that were confirmed or were not confirmed by western blot are shown in green and grey, respectively. b Western blot for HuR (top panels) of 
a subset of clones identified by dot blot. Bottom panel shows a control blot for Pum2 of the same membrane. Clone HuR-5.B5 is designated by a star
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ranging from 6 to 36  % of the initially tested clones. 
Knockout production was reproducible, as an inde-
pendent replicate of the experiment with guide RNAs 3 
and 4 yielded 10 and 8 % of null mutations respectively 
(data not shown), with the variability likely arising from 
transfection efficiencies. Considering that these lines 
represent concurrent editing of both alleles, and most 
likely require a frameshift mutation, the observed KO 
rates compare favorably with the ~6–50 % rates of over-
all NHEJ-driven indels measured by sequencing or the 
SURVEYOR assay using similar delivery methods [34, 
35]. The variability among the three tested sgRNAs also 
agrees with related observations for multiple guide RNAs 
at a given locus [24], presumably reflecting differences in 
sgRNA production, complex formation with Cas9, and 
targeting/cleavage efficiency [36]. However, CRISPR/Cas 
editing efficiencies may also show loci-specific variability, 
potentially explained by the dependence of Cas9 bind-
ing on chromatin accessibility, reflected in DNase hyper-
sensitivity and CpG methylation [37, 38]. Nevertheless, 
screening of a reasonably small number of initial clones 
is likely to produce more than one independent deletion 
mutant using this simple procedure.
Aside from targeting individual genes for knockout, 
the CRISPR/Cas system allows many additional means 
of genome editing. We assessed whether our screening 
protocol can be used to achieve simultaneous knockout 
of tandemly arranged genes by inducing large chromo-
somal deletions between two sgRNA target sites. Small 
deletions have been previously achieved without selec-
tion [24], while larger biallelic and monoallelic deletions 
have been created after sorting for strong Cas9 expres-
sion [39], or in haploid embryonic stem cells [40]. In our 
hands, attempts to excise the ~250 Kbp human Ago4, 1, 3 
locus by targeting Ago4 and Ago3 while blotting for Ago1 
have not yielded any complete deletions (data not shown). 
Thus, elimination of large genomic fragments may require 
the use of homologous recombination templates spanning 
the deletion, enrichment for cells expressing Cas9 (with-
out genomic insertion), and/or incorporation of selectable 
markers at the deletion site. Similarly, gene mutagenesis 
without deletion would require homologous templates 
involving selection or protein tagging. In these cases, dot 
blotting for the tag may still be used as a screening step. It 
should be pointed out that directly blotting for the protein 
under study is limited by antibody availability, and assay-
ing of secreted proteins may necessitate the collection of 
culture media instead of cell pellets.
Conclusions
The CRISPR/Cas system is transforming modern genetics 
and molecular biology by offering unprecedented ways of 
genomic manipulation. We have described a methodol-
ogy to isolate simple deletion mutants of a gene of inter-
est by CRISPR/Cas based on dot-blot screening for the 
resulting protein product, without the need for interven-
ing selection steps. The advantages of the method lie in 
the ease of upfront preparation (only the sgRNA con-
structs need to be created, based on short synthetic oli-
gonucleotides), the relative simplicity of the screening 
procedure, and the minimal genomic perturbations to 
the resulting clonal lines. For a typical knockout experi-
ment, our estimates indicate a time saving of 4–5  days 
relative to direct western blotting, or on the order of 
weeks relative to design and construction of selection 
steps. The protocol can be modified to allow for edit-
ing with homologous recombination templates, by blot 
screening for protein tags introduced on the template. 
The presented techniques should expand the available 
toolkit for the application of biochemistry and molecular 
and cell biology approaches to the study of protein func-
tion in mammalian cell culture.
Fig. 4 Sequence of the genomic deletions in clone HuR-5.B5. The genomic region surrounding the targeted site was PCR-amplified from wt 293-
TREx cells and clone HuR-5.B5, and placed into a plasmid vector. Individual plasmid clones were sequenced. The Cas9 cleavage site is denoted by a 
red triangle











HuR-3 69 15 22
HuR-4 22 8 36
HuR-5 157 9 6
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Methods
Preparation of Cas9‑sgRNA plasmids
The pSpCas9(BB) plasmid was a gift from Feng 
Zhang (Addgene plasmid #42230). Single guide RNA 
sequences were constructed to target the pre-designed 
loci in the third, forth, and fifth exon of the HuR gene 
(HuR-3, TGTGAACTACGTGACCGCGA;HuR-4,CGGG 
CGAGCATACGACACCT;HuR-5,CCGGATAAACG 
CAACCCCTC) and cloned into the parental plasmid as 
previously described [28]. Clones were tested for correct 
inserts using Sanger sequencing.
Cell Culture, transfections, and dilutions
293-TREx cells were grown in Dulbecco’s Modification 
of Eagle’s Medium (DMEM) with 4.5 g/L glucose, l-glu-
tamine and sodium pyruvate (Corning Cellgro Ref:10-
013-CV) that was supplemented with 10 % Fetal Bovine 
Serum (HyClone FBS Characterized Cat: SH30071.03) 
and 10 units/ml of Penicillin–Streptomycin (HyClone 
Cat: SV30010). Cultured plates were grown in a humidi-
fied incubator supplying 5 % CO2 at 37 °C.
Two independent transfection events were performed 
for each construct. First, cells were grown in a 6-well for-
mat to approximately 60  % confluency and transfected 
with 2.5  µg of the prepared Cas9-sgRNA plasmid using 
the calcium phosphate method. 24 h later cells were pas-
saged into 10  cm plates.  24  h following passaging, cells 
were again transfected with 12.5  µg plasmid using the 
TransIT-LT1 reagent (Mirus, Cat: MIR 2300). Cells were 
allowed to reach 100  % confluency before seeding out 
into individual clones. After the transfections, efficiency 
was estimated to be 70–80 % by GFP expression in a par-
allel transfection with a modified version of the pMSCV-
PIG vector.
To isolate individual clones, cells were seeded at a den-
sity of 3–5 cells per 96-well. Colony growth in less that 
60  % of the wells was observed over 3–4  weeks, and 
media was changed weekly to prevent drying of wells. 
Clone colonies that were visible to the eye were picked 
into 96-well plates by aspirating the media, dispens-
ing 2 µl of fresh media onto the colony, scraping across 
the colony with the pipette tip, and drawing the media 
back. 24–48 h later, isolated clones that were growing as 
a clump were reseeded by pipette mixing in the well to 
encourage monolayer cell growth.
Dot blot and western blot
Individual clones were grown until 100  % confluency 
and collected for dot blot analysis, dislodging the mon-
olayer of cells by pipeting within the well. 90  µl of the 
100 µl total volume was then removed, spun down, and 
the cell pellet lysed in 10  µl of 1×  Passive Lysis Buffer 
(Promega’s Dual-Luciferase Reporter Assay System, Cat: 
E1910). The remainder of the cells were propagated. 
1  µl of cell lysate was pipetted onto dry nitrocellulose 
membrane (Bio-Rad, Cat: 162-0115) to form a dot. Each 
sample was blotted twice on two separate membranes, 
creating two identical patterns of samples, blocked in 
5 % milk in TBST for 1 h at room temperature, and blot-
ted for HuR (Santa Cruz Biotechnology, clone 3A2, Cat: 
sc-5261, 1:1000–1:5000 dilution) and Pum2 (Bethyl Labs, 
Cat: A300-202A, 1:1000 dilution) in 5 % milk in TBST for 
1 h, with 3 × 5 min TBST washes in between incubation 
steps. Anti-Mouse-HRP-conjugated secondary antibody 
was from Cell Signaling (anti-mouse, Cat: 7076). Anti-
Rabbit-HRP-Conjugated Secondary Antibody was from 
Cell Signaling (anti-rabbit, Cat: 7074). Blotted mem-
branes were imaged on a Biorad ChemiDoc MP imager 
and quantified by Image Lab: identical circles were cen-
tered on each dot, and the signal volume was computed 
by the software. Local background values for each dot 
were computed and subtracted by Image Lab. Western 
blotting was performed as described above.
Sequencing of genomic DNA
To amplify a genomic fragment flanking the HuR-5 target 
region, primers were designed containing BbsI restriction 
sites with distinct overhangs (HuR-5 For, CGACTTGAAG 
ACCTCACCTGTGATGGGCTCAGAGGAACC; HuR-5 
Rev, CGACTTGAAGACCTAAACAGACTTCTAGCCTG 
GCCCAC). Genomic DNA of the parental 293-TREx line 
and the HuR-5.B5 mutant was isolated by standard SDS/
Proteinase K lysis followed by phenol/chloroform extrac-
tion and isopropanol precipitation. The target region was 
PCR amplified using Q5 High Fidelity DNA Polymer-
ase (New England Biolabs, Cat:M0491S), and cloned by 
Golden Gate cloning into a modified pRL-TK plasmid 
bearing two consecutive BbsI sites (ThermoFisher Scien-
tific Cat# FERFD1014). Isolated bacterial colonies were 
mini-prepped and Sanger sequenced.
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